Trajectories of Survivors and Non-Survivors Post-burn Injury.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 40519005.
- Also identified by DOI 10.1097/SLA.0000000000006787.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To gain insights into the systemic response after burn injury, we aimed to characterize the phases of inflammatory and metabolic trajectories in survivors and non-survivors. Survival after burn injuries has improved over the past few decades. However, a large proportion of the patients do not survive. This was a single-center cohort study. We included patients (aged ≥ 18 years) with burn injuries (≥ 10% total body surface area; TBSA) admitted to our provincial burn center. Clinical outcomes, laboratory measures, and inflammatory biomarkers were compared among survivors, early non-survivors (died ≤4 days post-injury), and late non-survivors (died ≥5 days post-injury). We studied 872 patients with a median age of 49 (Interquartile Range, IQR: 35-63) years and a median percent TBSA burn of 19% (IQR: 13-34) TBSA burn for survivors (n=705; 81%), early non-survivors (n=99; 11%), and late non-survivors (n=68; 8%). The median ages were 46 (IQR: 33-59) years for survivors, 62 (IQR: 46-73) years for early non-survivors, and 67 (IQR: 54-76) years for late non-survivors (P<0.0001). The median % TBSA burn was 17 (IQR: 13-26) for survivors, 67 (IQR: 43-88) for early non-survivors, and 27 (IQR: 18-44) for late non-survivors (P<0.0001). Non-survivors exhibited significantly elevated biomarkers compared to survivors, with distinct metabolic and inflammatory profiles, including increased IL-1β, IL-8, TNF-α, and IL-10. Late non-survivors experienced higher complication rates (P<0.01), with significant differences in inflammatory and metabolic responses over time. Survivors and non-survivors showed distinct post-injury inflammatory and metabolic responses. Identifying the relationship between concomitant immune activation and suppression among survivors and non-survivors may improve patient outcomes by defining and altering inflammatory trajectories. Elucidating the differences in trajectories between early and late non-survivors could allow for the prediction and identification of patients at risk of mortality.